Compare COOK & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COOK | ALXO |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.0M | 205.9M |
| IPO Year | 2021 | 2020 |
| Metric | COOK | ALXO |
|---|---|---|
| Price | $73.83 | $2.07 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $53.00 | $3.50 |
| AVG Volume (30 Days) | 49.0K | ★ 1.9M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $559,520,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.07 | N/A |
| P/E Ratio | $68.36 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $0.44 |
| 52 Week High | $86.59 | $2.66 |
| Indicator | COOK | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 56.53 | 61.34 |
| Support Level | $59.25 | $1.99 |
| Resistance Level | $75.82 | $2.27 |
| Average True Range (ATR) | 7.58 | 0.17 |
| MACD | -0.37 | 0.07 |
| Stochastic Oscillator | 49.14 | 79.10 |
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.